Company: WHWK
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001628280-25-020311
Chunk: 46

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 46
---
| All directors and executive officers as a group (13 persons) (20) |     |                           |         | 23,334,244 |     |            | 49.9 | % |

* Indicates beneficial ownership of less than 1% of the total outstanding common stock.

<div align='center'>29</div>

(1) Based solely on a Schedule 13D/A, filed with the SEC on March 4, 2025 consists of (i) 2,849,402 shares of common stock that are held by Avoro Life Sciences Fund LLC (“Avoro Life Science Fund”), an investment fund managed by Avoro Capital Advisors LLC (“Avoro Capital”), (ii) 622,350 shares of common stock that are held by Avoro Ventures Fund L.P. (“Avoro Ventures Fund”), an investment fund managed by Avoro Ventures LLC (“Avoro Ventures”), (iii) 6,666,400 shares of common stock issuable upon the exercise of Pre-Funded Warrants purchased in the PIPE Financing by Avoro Life Sciences Fund, and (iv) 1,666,600 shares of common stock issuable upon the exercise of Pre-Funded Warrants purchased in the PIPE Financing by Avoro Ventures Fund. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause Avoro Life Science Fund and Avoro Ventures Fund, together with their affiliates, to beneficially own in excess of 19.99% of the number of shares of our common stock outstanding immediately after giving effect to such exercise. Avoro Capital has sole voting power and sole dispositive power with regard to the securities held by Avoro Life Sciences and Avoro Ventures has sole dispositive power with regard to securities held by Avoro Ventures Fund. Behzad Aghazadeh, a director of the Company, is the portfolio manager and controlling person at Avoro Capital and Avoro Ventures. The principal business address of each of Avoro Capital and Mr. Aghazadeh is 110 Greene Street, Suite 800, New York, NY 10012.

(2) Consists of (i) 3,278,917 shares of common stock purchased in the PIPE Financing by Averill Master Fund, Ltd. (“Averill Master Fund”), (ii) 421,083 shares purchased in the PIPE Financing by Averill Madison Master Fund, Ltd. (“Averill Madison Fund” and, together with Averill Master Fund, the “Averill Funds